Solomon Moshkevich appointed Chief Executive Officer to lead the company's next phase of expansionCompany separately reports third quarter 2026 financial resultsNatera, Inc. (NASDAQ:NTRA), a global leader in
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.
Recent Financial Highlights
Generated total
New data at SITC includes real-world analysis highlighting that Signatera can inform immunotherapy duration and optimize treatment
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine,
Findings show Signatera’s predictive and prognostic abilities in a cancer that carries recurrence rates of up to 60%, along with excellent performance of the test in both HPV-positive and HPV-negative subtypesNatera,
Supports serial testing in the surveillance setting for patients with early-stage HCC
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5,
Natera’s oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision
Analyses drawn from a large real-world database of patients underscore how genetic testing can support better care in chronic kidney disease (CKD)
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and
Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentationsSignatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of
Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of
TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc.
Designation supports the development of a blood-based assay intended to screen for various cancers
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its
First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced
Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera’s role in informing personalized care management, including radiotherapy treatments
Natera, Inc. (NASDAQ:NTRA), a
Trial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s investigational oral SERD, aiming to spare patients unnecessary
